Gaps in the implementation of COVID-19 mitigation measures could lead to development of new strains of antimicrobial resistant pathogens: Nigerian perspectiveCommentary Published on 2021-09-032022-10-28 Journal: The Pan African Medical Journal [Category] COVID-19, MERS, SARS, [키워드] acute respiratory syndrome adopted antibiotic Antibiotic resistance Antibiotics antimicrobial abuse antimicrobial agent Care caused common cold Community complicate conditions COVID-19 COVID-19 mitigation measure cross-sectional survey death development Diagnosis disease Endemic Escalation evaluate Evolution exposure feasible FIVE Gap Government HCWs Health Health care worker health condition illness implementation include increase in individual Intervention lockdown malaria medication microorganism new strain new virus Nigeria non COVID-19 patients pandemic disease pathogen Perspective Prevent Randomly responsible SARS-CoV-2 SARS-CoV-2 virus Secondary infection selected social distancing Spread Symptom Treatment virus Volume with COVID-19 [DOI] 10.11604/pamj.2021.40.12.23274 PMC 바로가기 [Article Type] Commentary
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspectiveOriginal Research Published on 2021-09-022022-10-28 Journal: Therapeutic Advances in Medical Oncology [Category] COVID-19, [키워드] Admission analysed Cancer cancer centres cancer patient Care co-morbidity Complete COVID-19 COVID-19 diagnosis COVID-19 pandemic Critical diagnosed with COVID-19 discharge discharge rate Eligible patients end-of life care (EOLC) end-of-life (EOL) Escalation European facilitated First wave had more hospital impacted IMPROVE IQR male median age outcome Palliative care pandemic Patient patients Patients with cancer Perspective psychological support receive reported Repository SARS-CoV-2 shown specialist speciality palliative care team (SPCT) Symptom therapy Treatment [DOI] 10.1177/17588359211042224 PMC 바로가기 [Article Type] Original Research
Hybrid COVID-19 segmentation and recognition framework (HMB-HCF) using deep learning and genetic algorithms딥 러닝 및 유전 알고리즘을 사용한 하이브리드 코로나19 세분화 및 인식 프레임워크(HMB-HCF)Article Published on 2021-09-012022-09-11 Journal: Artificial intelligence in medicine [Category] SARS, 유전자 메커니즘, 치료기술, 치료제, [키워드] Accuracy Algorithm applicability applied approach AUC classification CNN collected Computer science concerning Convolutional neural network convolutional neural network (CNN) COVID-19 Data augmentation (DA) dataset deep deep learning Deep learning (DL) Diagnosis disease dropout Escalation evaluate experiment generalization Genetic Genetic algorithm Genetic algorithms (GA) highest hybrid Infection learning limit lung Lungs majority mechanism Metrics nine optimization overfitting pandemic disease parameter Precision recall reported transfer Transfer learning (TL). was used [DOI] 10.1016/j.artmed.2021.102156 PMC 바로가기 [Article Type] Article
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2SARS-COV-2에 대한 강력한 항 바이러스 활성을 갖는 리보 뉴 클레오 사이드 유사체 인 EIDD-2801/MK-4482 (Molnupiravir)의 최초 인간 임상 시험의 가속화 된 인간 임상 시험.Randomized Controlled Trial Published on 2021-08-232022-08-13 Journal: Trials [Category] MERS, 임상, 치료제, [키워드] accelerated Accelerated start-up acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Antiviral antiviral activity antiviral agent approval causative agent Clinical data clinical trial Cohort cohorts collaboration Complete completion contract research organization coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 CRO daily dose described dose Dose escalation Dosing double-blind drug eight Escalation ethics committee fasted or fed state FDA FIH FIH study followed by food food-effect global pandemic healthy volunteer healthy volunteers initial initiated MAD MAD cohort MAD cohorts Medicine Medicines Medicines and Healthcare products Regulatory Agency MHRA molnupiravir multiple ascending dose Painter pharmacokinetic Phase 2 phase 2 dosing Phase 2 study phase 2/3 Phase I Placebo profile protocol Randomized REC receive receiving Regulatory Regulatory Authorities regulatory authority Research Ethics Research Ethics Committee respiratory Ribonucleoside analog SAD cohort Safe SARS-CoV-2 sequence Seven severe acute respiratory syndrome Coronavirus single ascending dose Sponsor subject submission supported timelines Tolerability United Kingdom US Food and Drug Administration were dosed working [DOI] 10.1186/s13063-021-05538-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Antidrug resistance in the Indian ambient waters of Ahmedabad during the COVID-19 pandemicCOVID-19 전염병 동안 인도 아메다바드 주변 해역의 약물 내성Article Published on 2021-08-152022-09-11 Journal: Journal of hazardous materials [Category] SARS, 치료기술, [키워드] ambient Antibiotics Antidrug resistance approved can not carried Consumption count COVID-19 COVID-19 pandemic drug drugs E. coli Efficiency environmental health Epidemiology Escalation Escherichia coli exhibited homogenous incidence increase increase in incubated India indicated less marker parameters plant Prevalence quinolone recorded SARS-CoV-2 SARS-CoV-2 gene SARS-CoV-2 genes SARS-CoV-2 genome Surveillance t -value Treatment unavailability use of antibiotics wastewater wastewater based epidemiology water water bodies [DOI] 10.1016/j.jhazmat.2021.126125 PMC 바로가기 [Article Type] Article
Precision Response to the Rise of the SARS-CoV-2 B.1.1.7 Variant of Concern by Combining Novel PCR Assays and Genome Sequencing for Rapid Variant Detection and SurveillanceSARS-CoV-2의 부상에 대한 정밀 대응 B.1.1.7 신속한 변이 검출 및 감시를 위한 새로운 PCR 분석과 게놈 시퀀싱을 결합하여 우려 변이Research Article Published on 2021-08-112022-09-10 Journal: Microbiology Spectrum [Category] MERS, SARS, 변종, 치료기술, 치료제, [키워드] 95% CI Accuracy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approach B.1.1.7 B.1.351 Canada cause coefficient concern coronavirus COVID-19 COVID-19 pandemic cross-reactivity demonstrated detect detection Escalation Evolution of SARS-CoV-2 faster Genome sequencing gold gold standard help high correlation identify immune response less limits Limits of detection Lineage Mutation N501Y N501Y mutation Negative predictive value novel P.1 Pathogens PCR PCR assay PCR assays Positive predictive value positive predictive values predictive values Prevent Rapid real-time reverse transcriptase respiratory respiratory pathogen response reverse transcriptase Sampling strategies sampling strategy SARS-CoV-2 SARS-CoV-2 variant sensitivities sensitivity Sequencing severe acute respiratory syndrome Coronavirus severe disease Specificities specificity spike gene strain Strains Surveillance susceptibility targets the SARS-CoV-2 Transmission variants variants of concern Variation virus VoC VOCs wild-type [DOI] 10.1128/Spectrum.00315-21 PMC 바로가기 [Article Type] Research Article
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 A phase 1 randomized clinical trialSARS-COV-2에 대한 mRNA- 지질 나노 입자 백신 후보의 안전성 및 면역 원성은 1 상 무작위 임상 시험Clinical Trial Published on 2021-08-102022-08-13 Journal: Wiener Klinische Wochenschrift [Category] MERS, SARS, 임상, 진단, [키워드] Belgium comparable convalescent sera CureVac CVnCoV CVnCoV dose CVnCoV doses CVnCoV vaccination dosage Dosage-dependent increases Dose-response elicited ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Escalation Frequency Germany Ghent group Hannover healthy IgG antibodies IgG antibody immune response immune responses immunogenicity increases in interim analysis intramuscular dose Lipid nanoparticle Lipid nanoparticles LNP Local local AEs Mild moderate Munich Neutralizing antibodies overlapped Phase 1 phase 1 study Placebo platform Protein randomized clinical trial RBD reactogenicity Receptor binding domain response Result S protein S‑protein Safe Safety SARS-CoV-2 SARS-CoV‑2 SARS-CoV‑2 neutralizing titer SARS-CoV‑2 neutralizing titers SARS-CoV‑2 S‑protein second dose sequence-optimized mRNA coding serious AEs seroconverted severity supplementary material systemic adverse event systemic adverse events systemic AEs Tübingen vaccination Vaccine vaccine candidate Volunteer was measured [DOI] 10.1007/s00508-021-01922-y PMC 바로가기 [Article Type] Clinical Trial
Update Advances on C-Reactive Protein in COVID-19 and Other Viral InfectionsImmunology Published on 2021-08-102022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, 신종인플루엔자, [키워드] adaptive advance Antibiotic therapy appear Bacterial sepsis C-reactive protein C-reactive protein (CRP cause clearance Clinical diagnosis Complication contribute coronavirus disease COVID-19 COVID-19 virus Critical CRP disease Disease progression Diseases elevated Escalation etiology explain highlight Host host innate immunity hyperinflammation illnesses Immunity in viral infections Inflammation inflammatory mediator inflammatory status information macrophage activation syndrome marker measure mechanical ventilation Mild mitigate Multiorgan dysfunction non-infectious Other outcome Pathogenesis Pathologies Predictive Prevent procalcitonin progression Protein Proteins responses serum CRP severe COVID-19 the disease translated Treatment viral infection viral infections viral-induced [DOI] 10.3389/fimmu.2021.720363 PMC 바로가기 [Article Type] Immunology
Prone Positioning Is Safe and May Reduce the Rate of Intubation in Selected COVID-19 Patients Receiving High-Flow Nasal Oxygen TherapyArticle Published on 2021-07-302022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] Acute respiratory failure Admission chest X-ray clinical benefit Clinical efficacy COVID-19 COVID-19 patient eligible Endotracheal intubation Escalation failure feasible HFNO High-flow nasal cannula Hospital stay hypoxemic IMPROVE initial intermediate intubation rate Lung Opacity mortality rate non-intubated patients Oxygenation Patient patients patients with COVID-19 positioning primary endpoint prone prone positioning Rate receiving reduce required respiratory Respiratory Support resulting Safe SARS-CoV-2 subject survival therapy Trial unit with COVID-19 [DOI] 10.3390/jcm10153404 PMC 바로가기 [Article Type] Article
Increase in recruitment upon integration of trial into a clinical care pathway: an observational study임상 치료 경로에 임상 시험 통합 시 모집인원 증가: 관찰 연구Observational Study Published on 2021-07-012022-09-11 Journal: BMJ Open Respiratory Research [Category] 임상, [키워드] 49 days Admission boost can be used CCP clinical care clinical trial collected COVID-19 COVID-19 therapy effective Escalation exacerbate Hospital admission Hospital admissions increase increase in independent independent of integration Intensive occurred pathway Patient Prevalence proportion Randomised Evaluation recruited recruitment Respiratory Support running severe COVID-19 significant increase significantly statistically significant therapy Trial [DOI] 10.1136/bmjresp-2021-000967 PMC 바로가기 [Article Type] Observational Study